Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents that modulate melanocyte differentiation and pigmentation.
There is an urgent need for safe and effective treatment options for modifying melanocyte function (melanin production) for therapeutic benefit including:
- Preventing and treating melanoma
- Increasing or decreasing pigmentation to correct genetic and acquired skin conditions
- Aesthetically desirable skin tanning or skin lightening
We believe Linnaeus can provide a novel class of therapeutics that can safely and effectively increase and decrease melanin production, drive differentiation and treat melanoma.